Skip to main content

Advertisement

Table 1 Baseline and clinical characteristics of patients and their correlation with grade ≥ 2 acute radiation pneumonitis

From: Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients

Characteristics No. of Patients
(N = 183) (%)
No. of Grade ≥ 2 RP
(N = 26) (%)
Odds Ratio 95% CI P Value*
Age
 ≤ 63 (Median) 98 (53.6) 13(50.0) Reference   
 > 63 (Median) 84(45.9) 13(50.0) 1.21 0.53–2.78 0.651
Gender
 Male 162(88.5) 20(76.9) Reference   
 Female 21(11.5) 6(23.1) 2.84 0.99–8.17 0.053
Smoking
 Never 42(23.0) 7(26.9) Reference   0.644
 Current 77(42.1) 12(46.2) 0.92 0.33–2.56 0.878
 Former 64(35.0) 7 (26.9) 0.61 0.20–1.90 0.397
Pathology
 Squamous 112(61.7) 19 (73.1) Reference   0.570
 Adenocarcinoma 30(16.4) 3(11.5) 0.54 0.15–1.98 0.355
 Small Cell 35(19.7) 3(11.5) 0.46 0.13–1.65 0.234
 Others 6(2.2) 1(3.8) 0.98 0.11–8.86 0.985
Stage
 I/II 14(7.7) 0(0) 0.00   0.999
 III 115(62.8) 20 (76.9) Reference   0.578
 IV 54(29.5) 6 (23.1) 0.59 0.22–1.58 0.295
Chemo
 No 25(13.7) 1(3.8) Reference   
 Yes 158(86.3) 25(96.2) 4.51 0.58–34.89 0.149
Surgery
 No 139(76) 20(76.9) Reference   
 Yes 44(24) 6(23.1) 0.94 0.35–2.51 0.901
PGTV Volume
 ≤ 135.1 (Median) 92(50) 13(50) Reference   
 > 135.1 (Median) 91(50) 13(50) 1.0 0.44–2.32 0.976
PTV Volume
 ≤ 543.6 (Median) 92(50) 17(65) Reference   
 > 543.6 (Median) 91(50) 9(35) 0.48 0.20–1.15 0.101
PGTV prescription
 ≤ 54 (Median) 113(62) 14(54) Reference   
 > 54 (Median) 70(38) 12(46) 1.46 0.63–3.38 0.373
PTV prescription
 ≤ 50 (Median) 161(88) 23(88) Reference   
 > 50 (Median) 22(12) 3(12) 0.95 0.26–3.46 0.935
  1. Abbreviation: PTV planning target volume, PGTV planning gross tumor volume, V5/20 volume of lung receiving a dose ≥5/20 Gy, MLD mean lung dose
  2. *By repeated analysis of variance test (ANOVA)